Sağ Saim, Yeşilbursa Dilek, Güllülü Sümeyye
Department of Cardiology, Uludağ University Faculty of Medicine, Bursa, Turkey.
Turk J Gastroenterol. 2014 Aug;25(4):429-32. doi: 10.5152/tjg.2014.7688.
Pulmonary arterial hypertension (PAH) that occurs in the setting of cirrhosis and portal hypertension is referred to as portopulmonary hypertension (PPHTN). Liver transplantation (LTx) is curative, but the presence of moderate-to-severe PPHTN may be a contraindication for transplantation because of the elevated risk of peri- and post-transplantation morbidity and mortality. We report a successful liver transplantation in a patient with liver cirrhosis after treatment of moderate-to-severe PPHTN with a combination of the dual endothelin receptor antagonist bosentan and the specific phosphodiesterase-5 inhibitor sildenafil.
在肝硬化和门静脉高压背景下发生的肺动脉高压（PAH）被称为门肺高压（PPHTN）。肝移植（LTx）具有治愈性，但中重度PPHTN的存在可能是移植的禁忌症，因为围手术期和术后发病及死亡风险会升高。我们报告了1例肝硬化患者在接受双重内皮素受体拮抗剂波生坦和特异性磷酸二酯酶-5抑制剂西地那非联合治疗中重度PPHTN后成功进行肝移植的病例。
